Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma
R Suzuki, Y Kitamura, D Ogiya, Y Ogawa… - International Journal of …, 2022 - Springer
Abstract RAS/RAF/MEK/ERK pathway inhibitors exhibit significant anti-tumor effects against
various tumor types, including multiple myeloma (MM), and they are predicted to play a …
various tumor types, including multiple myeloma (MM), and they are predicted to play a …
[HTML][HTML] Anti-tumor activities of the new oral pan-RAF inhibitor, TAK-580, used as monotherapy or in combination with novel agents in multiple myeloma
R Suzuki, Y Kitamura, Y Nakamura, H Akashi… - Oncotarget, 2020 - ncbi.nlm.nih.gov
Many RAS pathway inhibitors, including pan-RAF inhibitors, have shown significant anti-
tumor activities in both solid and hematological tumors. The pan-RAF inhibitor, TAK-580, is a …
tumor activities in both solid and hematological tumors. The pan-RAF inhibitor, TAK-580, is a …
[HTML][HTML] Next generation XPO1 inhibitor KPT-8602 for the treatment of drug-resistant multiple myeloma
JG Turner, JL Dawson, CL Cubitt, E Baluglo, S Grant… - Blood, 2015 - Elsevier
Purpose Human multiple myeloma (MM) remains an incurable disease despite relatively
effective treatments, including proteasome inhibitors, immunomodulator-based therapies …
effective treatments, including proteasome inhibitors, immunomodulator-based therapies …
MEK inhibitor, TAK-733 reduces proliferation, affects cell cycle and apoptosis, and synergizes with other targeted therapies in multiple myeloma
P De la Puente, B Muz, A Jin, F Azab, M Luderer… - Blood cancer …, 2016 - nature.com
The RAS/RAF/MEK (mitogen-activated protein kinase)/ERK (extracellular-signal-regulated
kinase) pathway is one of the main signaling systems that manage proliferation …
kinase) pathway is one of the main signaling systems that manage proliferation …
NS-398 enhances the efficacy of bortezomib against RPMI8226 human multiple myeloma cells
W Que, S Li, J Chen - Molecular Medicine Reports, 2013 - spandidos-publications.com
Bortezomib is commonly used in treating multiple myeloma (MM). However, a number of
patients develop resistance to bortezomib over time. Cox-2 is overexpressed in MM cells …
patients develop resistance to bortezomib over time. Cox-2 is overexpressed in MM cells …
[HTML][HTML] XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor …
JG Turner, T Kashyap, JL Dawson, J Gomez… - Oncotarget, 2016 - ncbi.nlm.nih.gov
Acquired proteasome-inhibitor (PI) resistance is a major obstacle in the treatment of multiple
myeloma (MM). We investigated whether the clinical XPO1-inhibitor selinexor, when …
myeloma (MM). We investigated whether the clinical XPO1-inhibitor selinexor, when …
Targeting both BET and CBP/EP300 proteins with the novel dual inhibitors NEO2734 and NEO1132 leads to anti‐tumor activity in multiple myeloma
KR Ryan, F Giles, GJ Morgan - European Journal of …, 2021 - Wiley Online Library
Objectives Two promising epigenetic therapeutic targets have emerged for the treatment of
hematologic malignancies, BET and CBP/EP300 proteins. Several studies have shown that …
hematologic malignancies, BET and CBP/EP300 proteins. Several studies have shown that …
TAS-117, a novel selective Akt inhibitor demonstrates significant growth inhibition in multiple myeloma cells in vitro and in vivo
Abstract Abstract 942 The PI3K/Akt pathway mediates multiple myeloma (MM) cell growth
and drug resistance, and targeting this molecule is a promising therapeutic option. In this …
and drug resistance, and targeting this molecule is a promising therapeutic option. In this …
Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma
M Rizk, O Rizq, M Oshima, Y Nakajima‐Takagi… - Cancer …, 2019 - Wiley Online Library
Abstract Polycomb repressive complex 2 (PRC2) components, EZH2 and its homolog EZH1,
and PI3K/Akt signaling pathway are focal points as therapeutic targets for multiple myeloma …
and PI3K/Akt signaling pathway are focal points as therapeutic targets for multiple myeloma …
Preclinical activity of dual PI3K/mTOR inhibitor SPR965 in multiple myeloma
JT Larsen, V Ramakrishnan, J Haug, T Kimlinger… - Cancer Research, 2015 - AACR
Introduction: Relapsed and refractory multiple myeloma (MM) remains a significant clinical
challenge and drugs with new mechanisms of action to overcome resistance are needed …
challenge and drugs with new mechanisms of action to overcome resistance are needed …